학술논문
Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease.
Document Type
Academic Journal
Author
Belitskaya-Lévy I; VA Cooperative Studies Program Palo Alto Coordinating Center, VA Palo Alto Healthcare System, Mountain View, CA, USA.; Dysken M; VA Minneapolis Health Care System, Minneapolis, MN, USA.; Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.; Guarino P; VA Cooperative Studies Program West Haven Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA.; Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Sano M; Bronx Veterans Medical Research Center, New York, NY, USA.; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Asthana S; William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.; University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.; Vertrees JE; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA.; Pallaki M; Louis Stokes Cleveland VAMC, Cleveland, OH, USA.; Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Llorente M; Washington DC VA Medical Center, Washington, DC, USA.; Georgetown University School of Medicine, Washington, DC, USA.; Love S; VA Minneapolis Health Care System, Minneapolis, MN, USA.; Schellenberg G; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Source
Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-8737 (Electronic) Linking ISSN: 23528737 NLM ISO Abbreviation: Alzheimers Dement (N Y) Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Introduction: Because apolipoprotein E (APOE) genotypes are known risk factors for Alzheimer's disease (AD), they have been measured in clinical trial participants to determine their effect on treatment outcome.
Methods: We determined APOE genotypes in a subset of subjects (N = 415) who participated in a randomized controlled trial of vitamin E and memantine in 613 veterans with mild-to-moderate AD.
Results: Similar to the primary study, substudy participants receiving vitamin E also had slower functional decline than those receiving placebo. Overall, there was no difference in the rate of functional decline between APOE ε4 allele carriers and noncarriers. A significant interaction was observed between treatment and the APOE genotype on AD progression: ε4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm.
Discussion: APOE genotypes may modulate AD treatment response and should be included in the design of future randomized controlled trials.
Methods: We determined APOE genotypes in a subset of subjects (N = 415) who participated in a randomized controlled trial of vitamin E and memantine in 613 veterans with mild-to-moderate AD.
Results: Similar to the primary study, substudy participants receiving vitamin E also had slower functional decline than those receiving placebo. Overall, there was no difference in the rate of functional decline between APOE ε4 allele carriers and noncarriers. A significant interaction was observed between treatment and the APOE genotype on AD progression: ε4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm.
Discussion: APOE genotypes may modulate AD treatment response and should be included in the design of future randomized controlled trials.